Authors:
Halimi, S
Rostoker, G
Altman, JJ
Attali, C
Beaune, J
Belorgey-Bismut, C
Bouldouyre-Magnier, AM
Cordonnier, D
Denis, C
Duranteau, L
Grimaldi, A
Guillausseau, PJ
Koenig, F
Lagrue, G
Monnier, L
Orgiazzi, J
Raucoules-Aime, M
Saltiel, H
Simon, D
Varroud-Vial, M
Citation: S. Halimi et al., Guidelines for medical treatment of type 2 diabetes: condensed text, J FR OPHTAL, 23(3), 2000, pp. 302-306
Authors:
Halimi, S
Rostoker, G
Altman, JJ
Attali, C
Beaune, J
Belorgey-Bismut, C
Bouldouyre-Magnier, AM
Cordonnier, D
Denis, C
Duranteau, L
Grimaldi, A
Guillausseau, PJ
Koenig, F
Lagrue, G
Monnier, L
Orgiazzi, F
Raucoules-Aime, M
Saltiel, H
Simon, D
Varroud-Vial, M
Citation: S. Halimi et al., Guideliness for drug treatment of type 2 diabetes mellitus, ANN ENDOCR, 61(2), 2000, pp. 168-173
Authors:
Halimi, S
Rostoker, G
Altman, JJ
Attali, C
Beaune, J
Belorgey-Bismut, C
Bouldouyre-Magnier, AM
Cordonnier, D
Denis, C
Duranteau, L
Grimaldi, A
Guillausseau, PJ
Koenig, F
Lagrue, G
Monnier, L
Orgiazzi, J
Raucoules-Aime, M
Saltiel, H
Simon, D
Varroud-Vial, M
Citation: S. Halimi et al., The treatment of type 2 diabetes. Report of the expert commitee of the AFSSAPS, DIABETE MET, 25(6), 1999, pp. 533-550
Authors:
Liu, G
Duranteau, L
Carel, J
Monroe, J
Doyle, DA
Shenker, A
Citation: G. Liu et al., Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor., N ENG J MED, 341(23), 1999, pp. 1731-1736